Midwife Licensure Exam Fundamentals of Care & the Health-Care Process — Medication Administration & Dosage CalculationStudy Notes

Before administering any medication, the nurse must understand basic pharmacologic principles. **Pharmacokinetics** describes what happens to the drug as it enters and travels through the body: absorption (entry into the bloodstream), distribution (movement to tissues), metabolism (chemical breakdown, primarily in the liver), and excretion (elimination, primarily through the kidneys). Understanding these processes helps predict how long a drug takes to work and when to monitor for effects. **Pharmacodynamics** describes the drug's action on the body—its mechanism of action, therapeutic effects (desired outcomes), side effects (predictable but usually mild effects), and adverse effects (harmful reactions that require intervention). A **therapeutic effect** is the intended beneficial outcome; for example, acetaminophen reducing fever. A **side effect** is a predictable consequence that may or may not be harmful (e.g., drowsiness from diphenhydramine). An **adverse effect** is unexpected or harmful and may require immediate action (e.g., hypotension from a vasodilator). An **allergic reaction** is an immune-mediated response ranging from mild rash to life-threatening anaphylaxis. **Onset** refers to the time from administration until the drug first produces an effect. **Peak** is when the drug reaches its maximum therapeutic concentration. **Duration** is how long the drug's effect lasts. These timing parameters guide when to schedule doses and when to monitor for therapeutic or adverse responses. The **half-life** (time for plasma concentration to fall by 50%) helps determine dosing intervals; drugs with short half-lives (like penicillin) need frequent dosing, while those with long half-lives (like digoxin) need less frequent dosing. In the Philippine healthcare context, where many patients have limited health literacy and resources, understanding these basics allows nurses to provide effective patient teaching, explain why certain medications are given at specific times, and recognize when a drug is not working as expected so they can escalate to the healthcare provider.

The **route of administration** is the path by which a medication enters the body. The choice of route depends on the drug's properties, the patient's condition, the desired onset of action, and patient factors. The nurse must know the correct technique, safety precautions, and expected outcomes for each route. Incorrect route selection or technique is a common medication error. **Oral (PO) Administration** is the safest and most convenient route. The drug is swallowed and absorbed through the gastrointestinal tract. Onset is slower than parenteral routes (usually 30 minutes to 2 hours), but it is well-tolerated. **Do not crush or chew enteric-coated tablets** (designed to dissolve in the small intestine to avoid gastric irritation or to protect the drug from stomach acid) or **sustained-release forms** (designed to release medication gradually); crushing them destroys their special formulation and may cause harm or ineffectiveness. For patients with swallowing difficulties (dysphagia), consider liquid formulations or discuss with the healthcare provider about an alternative route. Always verify the patient can swallow before giving oral medications. **Sublingual (SL) and buccal** routes involve placing medication under the tongue or against the cheek; the drug absorbs directly into the bloodstream, bypassing the gastrointestinal tract and liver metabolism (first-pass effect), resulting in faster onset. **Nitroglycerin** is classically given sublingually for acute angina because it works in 1-3 minutes. Never swallow sublingual tablets; they must dissolve in place. **Topical/Transdermal Administration** applies medication to the skin. Topical drugs (creams, ointments, gels) act locally on the skin. Transdermal patches (e.g., fentanyl, nicotine, hormone replacement) deliver medication through the skin into the bloodstream over many hours or days for systemic effect. **Always remove the old patch before applying a new one** to avoid overdosing. **Rotate application sites** to prevent skin irritation and ensure consistent absorption. **Inhalation** delivers medication directly to the lungs via aerosol, nebulizer, or metered-dose inhaler (MDI). Onset is rapid due to the large absorptive surface of lung tissue. **Bronchodilators** (e.g., salbutamol), **corticosteroids** (e.g., fluticasone), and **mucolytics** are commonly inhaled. Teach patients proper MDI or nebulizer technique to ensure adequate drug deposition in the lungs. **Instillation** applies medication in liquid form to accessible body cavities: **eye (ophthalmic), ear (otic), nose (nasal), and rectum**. For **eye drops**, instill into the **lower conjunctival sac** (not directly on the cornea, which is painful); gently press the inner canthus for 1-2 minutes afterward to block the lacrimal duct and increase absorption while reducing systemic absorption. For **ear drops in adults**, pull the pinna **upward and backward** to straighten the canal; **in children under 3 years, pull downward and backward**. For **nasal medications**, have the patient tilt the head back or to the side as indicated. **Rectal and vaginal** suppositories dissolve in the rectum or vagina, allowing local or systemic absorption. Rectal suppositories (e.g., acetaminophen, bisacodyl) are useful for patients who cannot take oral medications or need rapid absorption. **Vaginal** preparations are used for local infection treatment (e.g., metronidazole gel for bacterial vaginosis). Always wear gloves and explain the procedure to the patient. **Parenteral Administration** (injection) bypasses the GI tract and provides faster, more predictable absorption. Sites include intradermal, subcutaneous, intramuscular, and intravenous. Each has specific angles, volumes, and techniques detailed below.

Parenteral injection routes require aseptic technique, correct needle angle, appropriate site selection, and proper volume limits to prevent complications. Each route serves a specific purpose, and confusing routes is a serious medication error. **Intradermal (ID) Injection** deposits medication into the dermis (the layer of skin below the epidermis). The needle angle is **10–15 degrees**; use a short needle (e.g., 25-27 gauge, 3/8–5/8 inch). Volume is very small, typically **0.1 mL or less**. A **bleb or wheal** (a raised, blanched area) should form at the injection site; if no bleb forms, the injection was too deep. ID is used for **allergy testing, tuberculosis testing (Mantoux test), and some vaccines**. Always mark the site for later reading and instruct the patient not to massage or scratch the area. **Subcutaneous (SC or SQ) Injection** deposits medication into the loose connective tissue beneath the epidermis and dermis. The needle angle is **45–90 degrees** (45 degrees if thin patient or small needle, 90 degrees if normal adult with pinched skin). Use a needle 25-27 gauge, 5/8–3/4 inch long. Volume is typically **≤1 mL** (most commonly ~0.5 mL; larger volumes are painful and increase risk of tissue damage). Common SC medications include **insulin, heparin, enoxaparin, and epinephrine**. **Critical SC technique points:** - **Never aspirate (pull back the plunger)** after inserting the needle in SC heparin or enoxaparin injection; aspiration can cause hematoma (bruising) and is not necessary because you are not targeting a blood vessel. - **Never massage the injection site** after SC heparin or enoxaparin; massage increases bruising and hematoma formation. - **Rotate sites** to prevent lipohypertrophy (fatty tissue buildup) and ensure consistent absorption. For insulin, rotate between abdomen (preferred due to consistent absorption), upper arms, thighs, and buttocks; within each region, rotate to different spots. For **heparin/enoxaparin, inject into the lower abdomen, at least 5 cm (about 2 finger-widths) away from the umbilicus** to avoid large blood vessels. - **Pinch the skin** to lift the SC tissue away from muscle, unless using a 90-degree angle with a short needle in an obese patient. **Intramuscular (IM) Injection** delivers medication into muscle tissue for slower absorption than IV but faster than SC. The needle angle is **90 degrees** (perpendicular to the skin). Use a longer, larger-gauge needle (usually 22-25 gauge, 1–1.5 inches) because muscle is deeper than SC tissue. Adult volume can be up to **3 mL per injection site** (deltoid limited to **≤1 mL** due to smaller muscle mass); larger volumes are given in the ventrogluteal or vastus lateralis. IM medications include **antibiotics (penicillin G), vaccines, and hormone injections**. **IM Site Selection (Critical):** 1. **Ventrogluteal (gluteus medius)** — **PREFERRED and SAFEST for adults**. Located between the anterior superior iliac spine and the greater trochanter. Insert the needle perpendicular to the imaginary line connecting these landmarks. This site is away from major nerves and blood vessels, making it the safest choice. Use the palm method or finger method to locate: place your heel on the patient's greater trochanter, fingers point toward the anterior superior iliac spine; the injection site is in the center of the V formed by the thumb and fingers. 2. **Vastus Lateralis (quadriceps)** — located on the outer anterior thigh. PREFERRED for **infants and young children** because it is well-developed early and free of major nerves. Safe for adults but not preferred. Divide the thigh into thirds between the greater trochanter and knee; inject into the middle third on the lateral (outer) surface. 3. **Deltoid (shoulder)** — small muscle, used for **small volumes (≤1 mL)** and **vaccines**. Located on the outer lateral shoulder; palpate the acromion process (bony bump at the shoulder) and inject below it in the middle third of the muscle. Risk of hitting the radial nerve if injected too far medially or the axillary nerve if injected too far inferiorly. 4. **Dorsogluteal (gluteus maximus)** — **AVOID in modern practice** because it carries significant risk of injuring the **sciatic nerve** (can cause permanent nerve damage and paralysis if hit). It is deeper than the ventrogluteal, harder to localize precisely, and better alternatives exist. **Z-Track Technique** is used for **irritating or staining drugs** (e.g., iron dextran, chlorpromazine, some antibiotics) to prevent leakage into subcutaneous tissue, which can cause pain, tissue damage, or discoloration. After drawing up the medication, **attach a fresh needle** (the original needle may have medication on it that would stain tissue). **Displace the skin and SC tissue laterally** (sideways) by 1–2 cm using the side of your hand or fingers. **Insert the needle at 90 degrees** into the muscle, **inject the medication slowly**, **wait 10 seconds** to allow the medication to begin diffusing into muscle, **withdraw the needle**, and **release the skin** so it slides back over the injection track, sealing the medication in the muscle and preventing backleakage. Document Z-track use in the patient's record. **Common IM Medication Errors to Avoid:** - Do not give IM injections into areas of erythema (redness), edema (swelling), or infection; choose a different site. - Do not reuse needles; always use a fresh needle for injection to prevent dulling and tissue trauma. - Do not inject into an area where the patient has reduced sensation (e.g., from paralysis or neuropathy) because the patient cannot report pain or pressure sensation that might indicate nerve impingement.

**Intravenous (IV) Administration** delivers medication directly into the vein, providing immediate onset of action and complete bioavailability (100% of the drug reaches systemic circulation). This route is critical in acute care but carries the **highest risk** of medication errors and complications because there is no opportunity to correct the dose after administration. Under RA 9173, registered nurses in the Philippines are **legally authorized to establish peripheral IV lines and administer IV medications** in most healthcare settings, though some institutions may have additional policies. **IV Access Types:** 1. **Peripheral IV Catheter** — a plastic catheter inserted into a peripheral vein (usually in the forearm or hand). It is the most common route for IV medication in acute and chronic care. Sizes range from 24-gauge (smallest, used for neonates and older adults with fragile veins) to 18-gauge (largest, used for rapid transfusion). Standard sizes for adults are 20-22 gauge. Peripheral IVs typically last 72–96 hours (three to four days); change the site every 72–96 hours per infection-control guidelines to reduce phlebitis risk. 2. **Central Venous Catheter (CVC)** — inserted into a large central vein (superior vena cava, inferior vena cava) via the subclavian, jugular, or femoral vein. Used for long-term IV access, medications that are irritating to peripheral veins (e.g., potassium, chemotherapy, hypertonic solutions), or when peripheral access is unavailable. Types include **PICC line (peripherally inserted central catheter)**, **Hickman catheter**, and **tunneled catheters**. CVCs require strict aseptic technique and regular flushing to prevent clotting and infection. 3. **Implanted Venous Port** — a subcutaneous device accessed via a special needle (non-coring needle) for intermittent or long-term IV therapy (e.g., chemotherapy). Between uses, it is flushed with saline and heparin to maintain patency. **IV Fluid Types and Osmolality:** The **osmolality** (concentration of dissolved particles) of IV fluids determines their effect on fluid distribution between body compartments. - **Isotonic fluids** have the same osmolality (~300 mOsm/L) as plasma. They expand the **extracellular fluid (ECF) compartment** without shifting fluid between intracellular and extracellular spaces. Common examples: **0.9% sodium chloride (normal saline), lactated Ringer's solution, and D5W in the bag** (though D5W becomes hypotonic after dextrose is metabolized). Use for general fluid replacement, blood transfusions, and maintaining IV access. **D5W is isotonic in the IV bag but hypotonic after administration** because cells metabolize the dextrose, leaving free water that enters the intracellular compartment. - **Hypotonic fluids** have lower osmolality than plasma (~< 250 mOsm/L). They shift fluid **out of the vascular space into the intracellular compartment**, hydrating cells. Example: **0.45% sodium chloride (half-normal saline)**. Use cautiously in patients at risk for cerebral edema or elevated intracranial pressure (ICP); do not use in head trauma or neurosurgical patients because fluid shift into brain cells can worsen cerebral edema. - **Hypertonic fluids** have higher osmolality than plasma (> 350 mOsm/L). They pull fluid **out of cells and the interstitial space into the vascular compartment**, expanding intravascular volume and shrinking cell volume. Examples: **3% sodium chloride, 5% sodium chloride, D10W, D20W, D50W**. Use for severe hypernatremia, cerebral edema (pulls fluid out of brain cells to reduce swelling), or rapid fluid resuscitation in shock. **Infuse slowly via central line** (peripheral veins cannot tolerate hypertonic solutions; they cause phlebitis). Monitor closely for fluid overload, especially in patients with renal or cardiac dysfunction. **Lactated Ringer's (LR)** is a balanced crystalloid solution containing sodium, potassium, calcium, and lactate (which is metabolized to bicarbonate by the liver). It more closely mimics plasma electrolyte composition than normal saline and is preferred for massive fluid resuscitation and trauma in many protocols, including Philippine Emergency Medicine guidelines. **IV Medication Administration Methods:** 1. **IV Push (IVP) or Bolus** — medication injected directly into the IV line or into a running IV over a short time (usually seconds to a few minutes). Examples include **epinephrine** in cardiac arrest, **nitroglycerin** for acute angina, **furosemide** for acute pulmonary edema. Always verify the drug is safe to give IV push (some medications are too irritating), infuse at the recommended rate, and monitor for adverse effects. **Never give undiluted potassium chloride (KCl) IV push**; it can cause fatal cardiac arrhythmia. 2. **IV Infusion** — medication mixed in a larger volume of fluid (typically 50–250 mL) and infused over 15 minutes to several hours using gravity or a pump. Examples include **antibiotics, heparin, dopamine**. Always check **compatibility** before mixing multiple drugs in the same IV line or bag. 3. **Piggyback (secondary) infusion** — a smaller IV bag (usually 50–100 mL) hung higher than the primary IV line and infused into the primary line via a Y-connector. Used to give **intermittent medications** (e.g., antibiotic every 6 hours) while maintaining vascular access with the primary fluid. 4. **Continuous IV infusion** — medication mixed in a larger volume and infused continuously. Examples include **insulin infusions in DKA, dopamine in septic shock, heparin for anticoagulation**. Requires vigilant monitoring and often a dedicated pump.

The **Five Rights of Medication Administration** are the cornerstone of safe practice. Many organizations have expanded this framework to **Ten Rights** to address additional safety elements. These are non-negotiable standards for every dose, every time, regardless of the setting (hospital, clinic, home care, or community). **Right 1: Right Patient** Always verify the patient's identity using **two independent identifiers** as required by the Joint Commission (JC) and most Philippine healthcare accreditation standards. Examples of valid identifiers: **patient name + hospital ID number, name + date of birth, ID number + date of birth**. **Never use room number alone** as an identifier. Ask the patient to state their name and birth date, and compare with the medication label and patient's wristband. In emergency situations where a wristband is unavailable, document the reason and use alternative verified identifiers. **Right 2: Right Drug** Verify that the medication ordered matches what you are preparing. **Read the label three times:** (1) when removing the medication from storage/drawer, (2) when preparing/pouring the dose, and (3) at the bedside just before administering. Check for **look-alike/sound-alike names** (e.g., digoxin vs. digitoxin, hydroxyzine vs. hydralazine, atenolol vs. albuterol) to prevent selection of the wrong drug. If unsure about a drug name, spelling, or strength, consult a pharmacist or drug reference. If the patient questions whether a medication is correct, **stop and re-verify** before giving it; patient safety takes priority over workflow efficiency. **Right 3: Right Dose** Calculate the dose carefully and verify it matches the physician's order. Use a calculator if needed (mental math errors are common). Always **double-check high-alert medications** (insulin, heparin, opioids, KCl, chemotherapy) by a second licensed professional before administration. Verify the dose is within the **safe dose range** for the patient's age, weight, renal function, and hepatic function. For **weight-based dosing**, confirm the patient's weight in **kilograms** and the prescribed dose in **mg/kg**, then calculate; always ask, "Is this dose reasonable for this patient?" If the calculated dose seems unusually high or low, recheck the calculation and consult the prescriber. **Right 4: Right Route** Administer the medication via the **exact route prescribed** (IV, IM, SC, PO, sublingual, etc.). Different routes produce different rates of absorption and drug levels; the wrong route can result in subtherapeutic or toxic levels. For example, **oral metformin is metabolized by the GI tract**, whereas **IV contrast dye would damage the kidney** if given orally. If a route seems inappropriate for the patient (e.g., IM injection in a patient on anticoagulation therapy due to bleeding risk), clarify with the prescriber before administration. **Right 5: Right Time and Frequency** Administer the medication at the **scheduled time** (or as close as possible per facility protocol, usually within 30 minutes before or after the scheduled time for non-critical drugs). Timing affects drug levels and therapeutic outcomes. For example, **antibiotics must be given at regular intervals** to maintain therapeutic blood levels; inconsistent timing reduces effectiveness and increases resistance risk. **Take-with-food and take-on-empty-stomach** instructions affect absorption timing. Understand the **rationale for timing**; for example, **ACE inhibitors are often given at bedtime** because they lower BP, and **iron supplements are best absorbed on an empty stomach**. If the patient is NPO (nothing by mouth) for surgery, **hold oral medications** per the preoperative protocol, but clarify which critical medications (e.g., cardiac drugs, seizure medications) should be given with a sip of water. **Right 6: Right Documentation** **Chart immediately after administering the medication, never before.** This ensures accuracy and legal protection. Documentation should include: (1) the drug name, dose, and route; (2) the date and time of administration; (3) the site of injection (for parenteral medications); (4) the patient's response or any adverse effects; (5) your signature and credential; and (6) any special instructions or patient teaching given. If a dose is refused by the patient, document the refusal and the reason, notify the healthcare provider, and chart the outcome. If a medication error occurs, document the error on an incident report and in the patient's medical record according to facility policy (see **Error Reporting** section below). **Never alter a medication record after administration**; if correction is needed, follow facility protocol (usually drawing a single line through the error, initialing, and dating). **Right 7: Right Reason/Indication** Understand **why** the patient is receiving this medication. What is the clinical indication? What is the expected therapeutic outcome? For example, **acetaminophen is given for fever or pain; an ACE inhibitor is given for hypertension or heart failure**. If the indication seems unclear or inconsistent with the patient's diagnosis, verify the order. Understanding the reason also allows you to **assess the patient appropriately before giving the drug** (see Right 8) and to **evaluate the patient's response** after administration (see Right 9). **Right 8: Right Assessment (Pre-Administration)** Before administering certain medications, **assess and document relevant baseline parameters** to ensure safety and to provide a comparison after administration. Examples: - **Before digoxin** (a cardiac glycoside for heart failure and arrhythmias): **Check the apical pulse for one full minute**; hold the dose and notify the physician if the pulse is **< 60 bpm** (bradycardia is a sign of toxicity). Check for signs of heart failure (crackles, dyspnea, edema) to assess baseline status. - **Before antihypertensive medications** (e.g., ACE inhibitors, beta-blockers): **Check BP** using a consistent method (same arm, same position); if systolic BP is very low (e.g., < 90 mmHg) or if the patient is symptomatic (dizziness, syncope), **hold and notify** the prescriber. - **Before opioid pain medications** (morphine, codeine): **Check respiratory rate and depth**; hold and reassess if RR is < 12 breaths/minute or if the patient is heavily sedated, as opioids suppress respiration and can cause respiratory depression. - **Before NSAIDs** (ibuprofen, diclofenac): **Check for GI symptoms, bleeding, renal function**; avoid or use cautiously in patients with peptic ulcer disease, acute kidney injury, or on concurrent anticoagulation. - **Before aminoglycosides** (gentamicin, amikacin): **Verify renal function** (serum creatinine, estimated glomerular filtration rate); these are nephrotoxic and renally cleared; dose adjustment may be needed. - **Before beta-blockers**: **Check heart rate and BP**; hold if HR < 50 bpm or BP too low. - **Verify known allergies** before any drug administration; use a consistent method (ask the patient, check the allergy alert band or sticker, and review the medical record). **Right 9: Right Response/Evaluation (Post-Administration)** After administering medication, **monitor the patient for the expected therapeutic effect and for adverse effects**. Timing depends on the drug and route: - **After IV push** (e.g., nitroglycerin): assess within **5–10 minutes**. - **After IM or SC injection**: assess within **15–30 minutes** for most drugs. - **After oral medication**: assess within **30 minutes to 1 hour** (varies by drug). - **After topical or transdermal application**: assess per drug-specific guidelines (some effects take hours). Document the patient's **subjective response** ("chest pain resolved," "itching decreased") and **objective findings** (vital signs, physical findings, lab values if relevant). If the drug did not produce the expected effect or if adverse effects developed, **notify the healthcare provider** and **adjust the care plan** as needed. For example: - **After antihypertensive**: reassess BP; if still elevated, notify; if too low, support the patient (sit/lie down, increase fluids, elevate legs) and notify. - **After pain medication**: reassess pain using the patient's preferred scale; if pain unrelieved, offer additional comfort measures or notify for dose adjustment. - **After antibiotic**: monitor for resolution of infection signs (fever, wound drainage, WBC count); assess for allergic reaction or GI upset. **Right 10: Right to Refuse** The patient has the **legal and ethical right to refuse** any medication, even if prescribed. **You cannot force a patient to take a medication.** If a patient refuses: 1. **Do not administer the medication.** 2. **Explore the reason** for refusal (fear of side effects, cost, cultural/religious belief, preference for alternative). 3. **Provide education** about why the medication is important and address the patient's concerns respectfully. 4. **Notify the healthcare provider** of the refusal and the reason. 5. **Document the refusal** in the patient's medical record, including the reason and the time the provider was notified. 6. **Respect the patient's autonomy** while advocating for their health. Example: An elderly patient with hypertension refuses morning antihypertensive doses because they "cause too much urination." Instead of forcing the dose, the nurse should ask about side effects, explain that the diuretic effect helps reduce fluid overload, suggest taking the medication in the morning to minimize nighttime voiding, and notify the physician to discuss alternatives if the current regimen is unacceptable to the patient. **The Three Checks of the Label** (embedded in the Rights): For every medication, read the **label three times** to prevent selection errors: 1. **First check**: when removing the medication from storage (drawer, shelf, refrigerator). 2. **Second check**: when preparing the dose (pouring, drawing up into syringe, counting tablets). 3. **Third check**: at the **bedside, immediately before administering** to the patient. At this point, if anything is unclear, **stop and verify** before giving the medication. These three checks are your last line of defense against medication errors; do not skip them, even if busy.

**Dosage calculation is a quantitative skill that must be mastered to prevent medication errors.** Errors in calculation can result in underdosing (ineffective treatment) or overdosing (toxicity and harm). The NLE expects nurses to calculate **oral, parenteral, and IV doses accurately and quickly**. Always **verify your calculations, round appropriately, and use a calculator** when needed. **Core Formula: Desired/Have × Quantity (D/H × Q)** This is the most commonly used formula for computing medication doses: $$\text{Dose to Give} = \frac{\text{Desired (ordered) dose}}{\text{Dose on hand (available strength)}} \times \text{Quantity/Volume on hand}$$ **Desired (D)** = the dose prescribed by the physician (in mg, units, mEq, etc.). **Have (H)** = the strength of the medication available in the supply (what is on the medication label). **Quantity/Volume** = the number of tablets, mL, etc., that contains the "Have" dose. **Oral Tablet Example:** - **Order:** 500 mg of amoxicillin. - **On hand:** 250 mg per tablet. - **Calculation:** (500 mg ÷ 250 mg) × 1 tablet = 2 tablets. - **Answer:** Give 2 tablets. **Liquid Medication Example:** - **Order:** 375 mg of azithromycin (liquid suspension). - **On hand:** 250 mg per 5 mL. - **Calculation:** (375 mg ÷ 250 mg) × 5 mL = 1.5 × 5 = 7.5 mL. - **Answer:** Give 7.5 mL using a syringe (not a household spoon). **Injectable Medication Example:** - **Order:** 0.25 mg of digoxin IM. - **On hand:** 0.5 mg per mL. - **Calculation:** (0.25 mg ÷ 0.5 mg) × 1 mL = 0.5 mL. - **Answer:** Draw up 0.5 mL in a syringe. **Unit Conversions: Essential Memorizations** Always **convert to the same unit** before calculating. The following conversions are essential and should be memorized: - **1 gram (g) = 1,000 milligrams (mg)** - **1 milligram (mg) = 1,000 micrograms (mcg or µg)** - Therefore: **1 g = 1,000,000 mcg** (though this is rarely needed). - **1 kilogram (kg) = 1,000 grams (g)** - **1 kilogram (kg) = 2.2 pounds (lb)** - Formula to convert lb to kg: **kg = lb ÷ 2.2** - Formula to convert kg to lb: **lb = kg × 2.2** - **1 liter (L) = 1,000 milliliters (mL)** - **1 milliliter (mL) = 1 cubic centimeter (cc)** (though mL is preferred in modern practice). - **Household/approximate conversions:** - **1 teaspoon (tsp) = 5 mL** - **1 tablespoon (tbsp) = 15 mL** (or 3 tsp) - **1 fluid ounce (oz) ≈ 30 mL** (more precisely, 29.57 mL) - **1 grain (gr) = 65 mg** (used for some older medications like aspirin; 5 gr aspirin ≈ 325 mg). **Conversion Example:** - **Order:** 0.5 g of metformin. - **On hand:** 500 mg per tablet. - **Conversion:** 0.5 g = 0.5 × 1,000 = **500 mg**. - **Calculation:** (500 mg ÷ 500 mg) × 1 tablet = **1 tablet**. **Weight-Based Dosing** Many medications, especially in **pediatrics**, are dosed based on patient **weight in kilograms**. The formula is: $$\text{Dose} = \text{Ordered dose (mg/kg)} \times \text{Patient weight (kg)}$$ Always verify the dose is within the **safe dose range** before administration. **Weight-Based Dosing Example:** - **Order:** Cefazolin 25 mg/kg IV for a child weighing 40 pounds (for surgical prophylaxis). - **Step 1: Convert weight to kg:** 40 lb ÷ 2.2 = **18.2 kg**. - **Step 2: Calculate dose:** 25 mg/kg × 18.2 kg = **455 mg**. - **Verify:** Is 455 mg within the safe pediatric range for cefazolin? (Typically yes; pediatric ranges are 25–50 mg/kg per dose.) - **Step 3: Prepare the medication** from available strength (e.g., if 500 mg/mL available, draw up 0.91 mL). **Intravenous Flow-Rate Calculations** **For Electronic Infusion Pumps (mL/hour):** $$\text{Rate (mL/hr)} = \frac{\text{Total volume to be infused (mL)}}{\text{Total infusion time (hours)}}$$ **Pump Flow-Rate Example:** - **Order:** Infuse 500 mL of normal saline over 2 hours using an infusion pump. - **Calculation:** 500 mL ÷ 2 hours = **250 mL/hour**. - **Action:** Program the pump to deliver 250 mL/hour; monitor hourly. **For Gravity Infusions (Drops Per Minute, gtt/min):** Gravity infusions use a **macrodrip** or **microdrip** IV set, each with a different **drop factor** (the number of drops per mL). The nurse must know the drop factor from the IV set package or label. $$\text{Drops per minute (gtt/min)} = \frac{\text{Total volume (mL)} \times \text{Drop factor (gtt/mL)}}{\text{Total infusion time (minutes)}}$$ **Common Drop Factors:** - **Macrodrip sets:** 10 gtt/mL, 15 gtt/mL, or 20 gtt/mL (deliver larger drops; used for faster rates). - **Microdrip sets:** **60 gtt/mL** (delivers tiny drops; used for slower, more precise rates, especially in pediatrics and critical care). **Gravity Flow-Rate Example 1:** - **Order:** Infuse 1,000 mL of normal saline over 8 hours using a macrodrip IV set (15 gtt/mL). - **Calculate total minutes:** 8 hours × 60 minutes/hour = 480 minutes. - **Calculate gtt/min:** (1,000 mL × 15 gtt/mL) ÷ 480 minutes = 15,000 ÷ 480 ≈ **31 gtt/min**. - **Action:** Set the gravity drip to deliver approximately 31 drops per minute; recount periodically to verify the rate. **Gravity Flow-Rate Example 2 (Microdrip for slower rate):** - **Order:** Infuse 150 mL of D5W over 1 hour for a child using a microdrip set (60 gtt/mL). - **Calculate total minutes:** 1 hour × 60 minutes/hour = 60 minutes. - **Calculate gtt/min:** (150 mL × 60 gtt/mL) ÷ 60 minutes = **150 gtt/min**. - **Note:** Since the drop factor is 60, the mL/hour and gtt/minute are numerically the same for microdrip calculations (a helpful shortcut: for microdrip, gtt/min ≈ mL/hour). **Important Points About IV Calculations:** - **Round drops to the nearest whole number** because you cannot deliver a fractional drop. - **Recount the drops periodically** (every 30–60 minutes) because gravity rates drift due to changes in patient position, IV tubing kinking, or vein changes. - **Electronic pumps are preferred** over gravity infusions for accuracy, especially for critical medications and in pediatrics. - **If the calculated rate seems very fast or very slow, recalculate** and verify the order; if still unusual, contact the prescriber. **Concentration and Percentage Strength** Some medications are ordered by **percentage strength** (e.g., "1% lidocaine" or "10% dextrose"). Percentage strength indicates the **amount of drug per 100 mL of solution**: - **1% solution** = 1 g per 100 mL (or 10 mg per mL). - **10% solution** = 10 g per 100 mL (or 100 mg per mL). - **5% dextrose in water (D5W)** = 5 g of dextrose per 100 mL (or 50 mg per mL). **Example:** To prepare 0.5 g of lidocaine from a 1% solution: - 1% = 1 g per 100 mL = 10 mg per mL. - Dose desired: 0.5 g = 500 mg. - Calculation: 500 mg ÷ 10 mg/mL = **50 mL** of 1% lidocaine. **Common Calculation Errors to Avoid** 1. **Confusing mg and mcg:** These differ by 1,000. A dose of 0.1 mg is NOT the same as 0.1 mcg. Always verify units. 2. **Forgetting unit conversion:** If the order is in grams but the supply is in milligrams, convert first before calculating. 3. **Decimal placement errors:** A misplaced decimal (e.g., 5.0 vs. 0.5) results in a 10-fold error. **Use a leading zero (0.5 mg) and never use a trailing zero (not 5.0 mg)** to prevent this. 4. **Rounding errors:** Round only your **final answer** to a reasonable amount (e.g., 7.48 mL rounds to 7.5 mL; 7.44 mL rounds to 7.4 mL). Do not round intermediate calculations. 5. **Calculator errors:** **Double-check your entry** on the calculator; entering 500 ÷ 50 when you meant 500 ÷ 250 will give a wrong answer. 6. **Forgetting to multiply by volume:** The formula is D/H × Q; many nurses calculate D/H but forget to multiply by the quantity, giving a dose without units. 7. **Confusing dose with volume:** For example, if the order is "500 mg" and the supply is "250 mg per 5 mL," you give 10 mL (volume), not 500 mg (dose). The dose is 500 mg; the volume given is 10 mL. **Safety Tips for Dosage Calculation** - **Use a calculator** for all calculations; mental math is error-prone. - **Show your work** step-by-step so others can verify your calculation. - **Ask a colleague** to double-check high-alert medication calculations (insulin, heparin, KCl, digoxin, opioids) before administration. - **Verify the safe dose range** for the patient (age, weight, renal/hepatic function) before calculating; if the calculated dose seems outside the normal range, recalculate and verify with the prescriber. - **Write out units clearly** (use "units," not "U"; use "mcg," not "µg" alone without context). - **Be cautious with very small volumes** (< 0.5 mL); consider if a more concentrated solution is available or if the dose should be reconsidered. - **Be cautious with very large volumes** (> 50 mL per IM injection; >100 mL per IV bolus over < 5 minutes); these may be dangerous or impractical.

**High-alert medications** are those that carry significant risk of harm if given in error due to their narrow therapeutic index, potency, or critical effects. These drugs require **independent double-checks, special precautions, and heightened vigilance**. Understanding safe practices and antidotes is essential for the NLE and critical care. **Common High-Alert Medications:** 1. **Insulin** - **Safe practice:** Use only **insulin syringes** (marked in units, e.g., 0-100 units). Never use regular tuberculin or 3-mL syringes; the volume markings will not align with units, risking severe overdose or underdose. **When mixing insulin types, draw clear (fast-acting/regular) before cloudy (intermediate/NPH)**—remember "clear before cloudy" or "Regular then NPH." Inject SC in the abdomen (preferred for consistent absorption), upper arms, thighs, or buttocks; **rotate sites to prevent lipohypertrophy** (fatty lumps that impair absorption). **Never mix insulin with other medications** except per protocol (some insulins can be mixed; others cannot). - **Monitoring:** Check blood glucose **before administration** (especially before meals for regular insulin and before bed for NPH); assess for signs of hypoglycemia (shakiness, sweating, confusion, seizure) and hyperglycemia (thirst, polyuria, fruity breath in DKA). **Hypoglycemia is an acute emergency** treated immediately with **fast-acting carbohydrate** (glucose tablets, juice, or, if unconscious or unable to swallow, **glucagon IM**). - **Type confusion error:** Ensure the insulin type matches the order (e.g., do not give NPH when regular insulin was ordered, or vice versa); this is a critical error that affects blood glucose for hours. 2. **Heparin and Low-Molecular-Weight Heparins (LMWHs like enoxaparin)** - **Safe practice:** Heparin (unfractionated) is dosed in **units per kilogram per hour** and requires **continuous IV infusion** with close monitoring. **Never give IV push heparin without express order and verification**; the dose is too large. For **enoxaparin (Lovenox)**, a LMWH given SC, **do not aspirate or massage** after injection (increases bruising). Check patient weight for accurate dosing (enoxaparin is dosed 1 mg/kg or 1.5 mg/kg per dose). - **Monitoring:** Monitor for **bleeding** (hematuria, hematemesis, hemoptysis, easy bruising, nosebleeds, melena). For **unfractionated heparin, monitor activated partial thromboplastin time (aPTT)** regularly; therapeutic range is typically 1.5–2.5 times control (or 46–70 seconds depending on lab). For **enoxaparin, aPTT monitoring is usually not needed** (it is predictable dosing), but assess clinically for bleeding. - **Antidote:** **Protamine sulfate** reverses heparin within minutes; dose is 1–1.5 mg protamine per 100 units of heparin. Give IV slowly (over 5–10 minutes) as it can cause flushing, hypotension, and anaphylaxis if infused too fast. **Enoxaparin is only partially reversed by protamine** (~60% of anticoagulation is reversed). 3. **Warfarin (Coumarin anticoagulant)** - **Safe practice:** Warfarin is dosed based on **PT/INR (prothrombin time/international normalized ratio)**; therapeutic INR is typically 2–3 for most indications (higher for mechanical heart valves). **Dose the same time daily**. Multiple **food-drug and drug-drug interactions** affect warfarin metabolism; any new medication or significant dietary changes (especially vitamin K foods like greens) require INR rechecking. **Not reversible immediately** unlike heparin; effects take hours to reverse. If acute reversal is needed, use **fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC)** plus **vitamin K** (phytonadione). - **Monitoring:** Monitor **PT/INR regularly** (every 3–5 days after starting, then weekly, then monthly once stable). Assess for bleeding signs. **Teach the patient** to avoid NSAIDs, alcohol excess, and abrupt dietary changes, and to inform all providers (including dentists) about warfarin use. - **Antidote:** **Vitamin K (phytonadione)** reverses warfarin over 12–24 hours; gives 2.5–10 mg IV slowly (never as rapid IV bolus; causes severe hypotension). For acute life-threatening bleeding, also give FFP or PCC. 4. **Opioid Analgesics (Morphine, Codeine, Hydromorphone, etc.)** - **Safe practice:** Opioids depress **respiratory drive**; **always check respiratory rate and depth before administration**. Hold the dose and reassess if **RR < 12 breaths/minute** or if the patient is unresponsive to verbal or tactile stimuli (signs of respiratory depression). Titrate SC or IV opioids slowly, waiting 5–15 minutes between doses to assess effect. Monitor for **oversedation** (difficult to arouse, slurred speech). Patients on chronic opioids develop **tolerance** (need higher doses); avoid abrupt cessation (causes withdrawal: anxiety, sweating, body aches). - **Monitoring:** Assess pain response 15–30 minutes after administration (earlier for IV). Monitor bowel function; opioids cause **constipation**—consider prophylactic **stool softener** or **laxative**. Watch for **addiction** (psychological dependence) vs. **physical dependence** (expected with chronic use) vs. **tolerance** (need more drug for same effect). - **Antidote:** **Naloxone (Narcan)** is an opioid antagonist that **reverses opioid overdose within 2–3 minutes** of IV, IM, or SC injection. Dose is 0.4–0.8 mg IV (may repeat every 2–3 minutes if no response). **WARNING: Naloxone precipitates acute withdrawal** (severe anxiety, agitation, body aches, hypertension) in opioid-dependent patients; use only for life-threatening overdose (apnea, unresponsiveness). Naloxone's duration is shorter than many opioids, so the patient may slip back into respiratory depression after it wears off; monitor closely and repeat doses as needed. 5. **Potassium Chloride (KCl) — High-Alert** - **Safe practice:** **NEVER give KCl IV push undiluted** — it causes **fatal cardiac arrhythmia** (peak effect within 1 minute). **Always dilute KCl** in IV fluid (typically 10–20 mEq per 250–500 mL saline; never in D5W alone, which is hypotonic and causes cell lysis) and infuse **slowly via IV pump** (typical rate 10–20 mEq/hour; maximum 40 mEq/hour in emergency). **Never give SC or IM** (causes tissue damage and severe pain). **Verify the order carefully**; dose is in mEq (milliequivalents), not mg. **Always verify serum potassium before giving**; avoid if K+ is already elevated (hyperkalemia >5.5 mEq/L) as it worsens arrhythmia risk. - **Monitoring:** Assess IV site closely for infiltration; concentrated KCl is caustic to tissue and causes **severe phlebitis and extravasation injury**. Monitor **cardiac rhythm on monitor** if available. Assess for signs of hyperkalemia (weakness, palpitations, peaked T waves on EKG). **Check serum potassium after infusion** to verify response. - **No direct antidote**, but hyperkalemia is managed with **calcium gluconate** (stabilizes cardiac membrane), **insulin + dextrose** (drives K+ intracellularly), and **sodium bicarbonate** or **albuterol** (shifts K+ into cells). 6. **Chemotherapy Agents** - **Safe practice:** **Double-check all chemotherapy calculations and doses** with another oncology nurse before administration. Verify the **patient's body surface area (BSA)** is used correctly (many drugs are dosed in mg/m² BSA). **Many chemotherapy drugs are vesicants** (cause severe tissue damage if extravasated); use a **central line** (e.g., PICC or port) when possible. Infuse **slowly** and monitor closely. **Assess for extravasation** (pain, swelling, blanching) immediately and stop infusion if suspected. - **Monitoring:** Monitor for **acute toxicities** (nausea, vomiting, alopecia, bone marrow suppression, cardiotoxicity, mucositis) and **chronic toxicities** (secondary malignancy, infertility). Educate the patient about side effects and when to seek help. - **Antidotes vary** by drug; some extravasations require **dimethyl sulfoxide (DMSO)** or other topical agents; notify oncology immediately if extravasation occurs. 7. **Digoxin (Cardiac Glycoside for Heart Failure and Atrial Fibrillation)** - **Safe practice:** **Check apical pulse for full 60 seconds before every dose**; **hold and notify the physician if pulse < 60 bpm** (bradycardia is a sign of toxicity). Digoxin has a **narrow therapeutic index** (therapeutic level 0.8–2.0 ng/mL; toxicity > 2.0 ng/mL, though symptoms can occur in the therapeutic range, especially if hypokalemia is present). **Hypokalemia and hypomagnesemia increase digoxin toxicity risk** even at normal serum levels. **Renal function affects digoxin clearance**; reduce dose in elderly or those with renal impairment. - **Monitoring:** Monitor **heart rate and rhythm** (digoxin toxicity causes PVCs, bigeminy, AV blocks). Assess for **nausea, vomiting, anorexia, visual disturbances** (yellow vision is classic but rare), and weakness—all signs of toxicity. **Check serum digoxin level** if toxicity suspected (draw 6–8 hours post-dose for accurate level). - **Antidote:** **Digoxin-specific antibody (DigFab)** binds digoxin and neutralizes it within minutes; used for life-threatening toxicity. **Dosing is based on serum digoxin level and patient weight**; consult pharmacy for calculation. **Safe Practices for All High-Alert Medications:** 1. **Use standardized concentrations** (e.g., limit insulin strengths in a unit to U-100 only; do not stock U-500 unless absolutely necessary). 2. **Label all medications and infusions clearly** with the drug name, dose, time prepared, and your initials. 3. **Perform independent double-checks**: two licensed nurses verify the order, calculations, and dose before administration (especially for IV high-alert drugs). 4. **Use alerts or flags** on the patient's chart (e.g., "Anticoagulation on board," "Diabetic on insulin"). 5. **Educate the patient** about the medication's purpose and what side effects to expect. 6. **Monitor closely after administration** and document response. 7. **Report errors immediately** per facility incident-reporting protocol; the priority is **patient safety**, not blame.

**Intravenous therapy complications** range from minor (infiltration) to life-threatening (sepsis, air embolism). Early recognition and prompt intervention prevent patient harm and maintain IV access. The nurse must **assess the IV site hourly** (or per protocol) and respond immediately to complications. **Common IV Complications and Nursing Interventions:** **1. Infiltration** - **Definition:** IV fluid leaks from the vein into surrounding subcutaneous tissue. - **Causes:** Catheter displacement (movement), small vein rupture, or poor catheter tip placement. - **Signs:** Swelling (edema) around the IV site, coolness of the area (fluid is room temperature), pallor, absence of blood return when aspirated, **decreased flow rate or no flow**, patient reports pain or pressure at the site. - **Risk:** Hypertonic or irritating fluids (potassium, chemotherapy) can cause **tissue necrosis** if infiltrated. - **Nursing action:** 1. **Stop the infusion immediately**; disconnect the tubing. 2. **Remove the catheter** carefully; do not reinsert into the same vein. 3. **Elevate the extremity** above heart level to reduce swelling. 4. **Apply a compress:** warm compress (if the fluid is nonirritating like normal saline) or **cool compress** (if the fluid is potassium or other irritating substance); see facility protocol. 5. **Notify the healthcare provider** if a large volume infiltrated or if the fluid is vesicant (chemotherapy, hypertonic solutions); antidote therapy may be needed (e.g., **hyaluronidase injected into infiltrated tissue** for some chemotherapy agents). 6. **Establish a new IV** in the opposite extremity if ongoing IV access is needed. 7. **Document** the time, amount infiltrated (estimate if unknown), signs/symptoms, actions taken, and patient response. 8. **Assess for complications** over the next hours/days (tissue damage, infection, compartment syndrome if large volume). **2. Phlebitis** - **Definition:** Inflammation of the vein; may be **mechanical** (catheter irritation), **chemical** (irritating drugs), or **septic** (bacterial infection). - **Causes:** Prolonged catheterization (>72–96 hours), irritating drugs infused peripherally (potassium, hypertonic solutions, some antibiotics), poor catheter insertion technique, or contamination. - **Signs (Phlebitis Scale):** - **Grade 1 (Minimal):** Erythema at site, no other signs. - **Grade 2 (Mild):** Erythema + pain on palpation over vein. - **Grade 3 (Moderate):** Erythema + pain + palpable cord (hardened vein segment extending from site). - **Grade 4 (Severe):** All of above + purulent drainage (pus), cellulitis, or **systemic signs of infection** (fever, leukocytosis)—this is **septic thrombophlebitis**. - **Nursing action:** 1. **Stop the infusion.** 2. **Remove the catheter** and culture the tip if phlebitis is severe or septic (send to lab). 3. **Apply a warm compress** to the affected area for comfort (heat increases blood flow and reduces inflammation in mechanical/chemical phlebitis; in septic phlebitis, this may not help and isolation of the site is preferred). 4. **Establish a new IV** in a different site (opposite arm or different location). 5. **Notify the healthcare provider** if phlebitis is grade 3 or higher or if septic thrombophlebitis is suspected (may require **IV antibiotics**). 6. **Document** the assessment, grade, actions, and patient response; note the date/time of catheter removal. 7. **Assess frequently** for worsening (increasing pain, cellulitis spreading, systemic signs) and response to warm compress. **3. Extravasation (Vesicant Drug Infiltration)** - **Definition:** A **vesicant or caustic medication** leaks into subcutaneous tissue, causing tissue damage, necrosis, and potential loss of limb function if severe. - **High-risk drugs:** **Chemotherapy** (doxorubicin, vinblastine, paclitaxel), **potassium chloride, hypertonic dextrose, some antibiotics** (e.g., nafcillin, vancomycin), **vasopressors** (norepinephrine, dopamine). - **Signs:** **Acute pain at IV site** (more severe than infiltration; may be burning or stinging), swelling, erythema, tissue blistering or darkening (necrosis) within hours to days. - **Nursing action (MEDICAL EMERGENCY):** 1. **Stop the infusion immediately.** 2. **Do NOT remove the catheter immediately** if possible; leave it in place to allow for antidote administration through the IV. 3. **Notify the physician/oncology team STAT** (this is urgent). 4. **Aspirate residual drug** from the IV catheter (gently pull back on the plunger to withdraw remaining medication); this limits further leakage. 5. **Administer antidote if available** through the IV catheter or by SC injection around the infiltrated area per protocol. Examples: - **Hyaluronidase** (breaks down hyaluronic acid in tissue, allowing drug diffusion) for some chemotherapy (doxorubicin, paclitaxel, vincristine). - **Sodium thiosulfate** for certain agents (mechlorethamine). - **Dimethyl sulfoxide (DMSO)** for some agents. 6. **Apply cold compress** (ice pack wrapped in cloth) to the area **for the first 15–20 minutes** to slow drug absorption and local damage; then switch to **warm compress** per protocol (protocols vary; follow facility antidote protocol). 7. **Elevate the extremity** above heart level. 8. **Remove the IV catheter** once antidote is instilled and per protocol. 9. **Document** the drug, estimated volume, time of extravasation, antidote given, and timeline. Take a **photo** of the site if facility policy permits (provides baseline for tracking tissue damage). 10. **Arrange follow-up** with plastic surgery if tissue damage is extensive; serial assessments monitor for necrosis and the need for surgical debridement. **4. Fluid Overload (Circulatory Overload)** - **Definition:** Excessive IV fluid administration overwhelms the patient's ability to regulate fluid balance, causing **hypervolemia** (excess intravascular fluid). - **Risk patients:** Those with **renal impairment** (cannot excrete excess fluid), **heart failure**, **liver disease**, **cardiogenic shock**, or **elderly** (reduced compensatory capacity). - **Causes:** Too-rapid infusion rate, excessive total volume, prolonged IV therapy. - **Signs (classic triad):** 1. **Respiratory:** Dyspnea, tachypnea, orthopnea (shortness of breath when lying down), paroxysmal nocturnal dyspnea, **crackles on auscultation** of lung bases (fine crackling sounds from pulmonary edema). 2. **Cardiovascular:** Hypertension (elevated BP due to increased intravascular volume), **bounding pulse** (strong, full pulse due to increased stroke volume), **distended neck veins (JVD)**, peripheral edema, weight gain (>2–3 lb per day). 3. **Other:** Headache, confusion (from cerebral edema if severe), restlessness. - **Nursing action:** 1. **Slow the IV rate immediately** to a **keep-vein-open (KVO) rate** (usually 10–20 mL/hour to maintain patency without further fluid loading); notify the physician. 2. **Raise the head of the bed (HOB)** to 30–45° or higher (semi-Fowler's or high Fowler's position) to ease breathing and reduce pulmonary edema. 3. **Assess respiratory status:** rate, depth, oxygen saturation; **apply oxygen** if SpO2 < 90% per provider order. 4. **Assess for adventitious sounds** (crackles, wheezes, rhonchi) and report changes. 5. **Monitor vital signs** closely: BP, HR, RR, SpO2. 6. **Restrict fluid intake:** clarify with the physician the **daily fluid limit** (often 800–1000 mL); count all intake (IV, oral, medications in suspension). 7. **Weigh daily** at the same time, same scale, same clothing; report gains > 1–2 lb per day. 8. **Monitor urine output** closely; report oliguria (low output) or anuria (no output). 9. **Prepare for diuretics:** the physician may order **furosemide IV** or other diuretics to promote fluid excretion. 10. **Position for comfort** and to maximize chest expansion. 11. **Provide emotional reassurance** (dyspnea is frightening). 12. **Document** all interventions, patient response, and vital signs. **5. Air Embolism** - **Definition:** Air bubble enters the vein and travels to the pulmonary circulation, causing **acute right ventricular obstruction** and potentially fatal **cardiopulmonary collapse**. - **Causes:** Disconnect IV tubing from the catheter hub, rapid IV administration with air in the line, failure to purge air from a central line during insertion or flushing. - **Prevention:** **Always check for air bubbles before infusing** IV fluid or blood; prime all IV tubing with fluid; secure all connections; keep the catheter hub capped; train staff on proper IV technique. - **Signs (acute onset):** Dyspnea, chest pain, lightheadedness, tachycardia, hypotension, cyanosis, altered mental status (confusion, loss of consciousness), **characteristic "mill-wheel" heart murmur** (churning sound) on auscultation (rare but pathognomonic). - **Nursing action (MEDICAL EMERGENCY):** 1. **Clamp the IV catheter or tubing immediately** to prevent more air from entering. 2. **Place the patient in left lateral decubitus position (left side down, Trendelenburg 15°)** — this positions the right atrium lower than the left, trapping air in the right atrium/ventricle and preventing it from entering the pulmonary artery. 3. **Call for help; notify the physician STAT.** 4. **Apply high-flow oxygen** to improve oxygenation; prepare for possible intubation. 5. **Establish IV access** if not already present (for medications/fluids). 6. **Do CPR if pulseless**; air embolism can cause cardiac arrest. 7. **Transport to hyperbaric chamber** if available (reduces bubble size via increased pressure); notify the facility if they have this capability. 8. **Monitor continuously** for hemodynamic changes. **6. Speed Shock** - **Definition:** Severe systemic reaction from **too-rapid IV administration** of medication, causing immediate cardiovascular and CNS effects. - **Causes:** Infusing medication too quickly (especially vasoconstrictors, potassium, calcium, digoxin). - **Signs (within seconds to minutes):** Chest pain/tightness, palpitations, tachycardia, hypertension then hypotension, syncope, altered mental status, fever, flushing, **loss of consciousness.** - **Prevention:** **Always infuse medications at the prescribed rate or slower**; use IV pumps for critical drugs; know which medications must be infused slowly. - **Nursing action:** 1. **Stop the infusion immediately.** 2. **Assess vital signs and level of consciousness.** 3. **Keep the IV open** with normal saline at KVO rate. 4. **Apply oxygen.** 5. **Notify the physician.** 6. **Support the patient:** lay flat (unless contraindicated), elevate legs, provide reassurance. 7. **Prepare for advanced cardiac life support (ACLS)** if the patient develops cardiac arrhythmia or arrest. 8. **Document** the drug, infusion rate, time of onset, signs/symptoms, and interventions. **7. Catheter-Related Bloodstream Infection (CRBSI)** - **Definition:** Bacterial/fungal infection of the bloodstream originating from a central or peripheral IV catheter, causing **sepsis** if severe. - **Risk factors:** Prolonged catheterization (>72–96 hours for peripheral), poor insertion technique, non-sterile dressing changes, immunosuppression, hospitalization. - **Signs:** **Fever >38°C**, chills, malaise, positive blood culture, signs of sepsis (tachycardia, tachypnea, hypotension, altered mental status). - **Prevention:** **Strict aseptic technique during insertion**, sterile dressing, regular dressing changes (every 48–72 hours or if soiled/wet), catheter site assessment, timely catheter removal (do not leave in > 72–96 hours unless essential). - **Nursing action:** 1. **Suspect CRBSI if fever develops** after 48 hours of IV therapy. 2. **Notify the physician immediately.** 3. **Draw blood cultures** from peripheral puncture (not from the IV line, which is contaminated) and from the central line if present; culture the IV catheter tip after removal. 4. **Remove the catheter** per physician order; send the tip for culture. 5. **Prepare for IV antibiotics** (broad-spectrum initially; tailored after culture results). 6. **Reestablish IV access** in a new location if needed; avoid the infection site. 7. **Monitor vital signs, blood cultures, and response to antibiotics closely.** 8. **Document** the fever onset, interventions, catheter removal time, and follow-up cultures. **General IV Site Assessment (Hourly or Per Protocol):** Use a **standardized assessment tool** and document findings: - **Appearance:** Redness, swelling, bruising, drainage (clear, bloody, purulent). - **Feel:** Warmth, hardness (cord), tenderness. - **Function:** Blood return, flow rate, patient comfort. - **Dressing:** Intact, dry, clean; if saturated or soiled, change immediately. - **Tubing:** Kinked, disconnected, date of insertion (should be changed per policy, typically every 96 hours). - **Patient concerns:** Pain, pressure, numbness, tingling (signs of nerve compression or extravasation). **Documentation and Reporting:** For any IV complication: 1. **Document the time of discovery**, signs/symptoms, actions taken, and patient response. 2. **Notify the healthcare provider immediately** (not just at end of shift). 3. **Report to the charge nurse** for awareness and continuity of care. 4. **Photograph the site** if tissue damage is visible (per facility policy). 5. **Monitor the patient closely** for progression and complications.

Medication administration in special populations requires **age and condition-specific modifications** to standard dosing, routes, and techniques. Errors in these populations carry heightened risk because they are more vulnerable to adverse effects. **Pediatric Medication Administration** **Dosing:** - **Weight-based dosing (mg/kg)** is the standard in pediatrics because children's body composition, metabolism, and organ function differ from adults. Always **convert the child's weight to kilograms** (lb ÷ 2.2 = kg) and verify the dose is within the **safe pediatric dose range** for the child's age before administration. For example, the pediatric dose of amoxicillin is 25–45 mg/kg/day divided into doses; a 5-year-old weighing 20 kg would receive 500–900 mg/day total, divided into 2–3 doses. - **BSA-based dosing (mg/m²)** is used for some medications, especially **chemotherapy**. Body surface area is calculated using the child's height and weight (using nomograms or formulas); dosing is then mg/m² × BSA = total dose. This accounts for the child's **metabolic rate** better than weight alone. - **Always verify the safe dose range** after calculating and **question doses that seem unusual**. A dose that is double the usual range should prompt recalculation and verification with the prescriber. - **Never use adult doses for children**, even if the child is large; age-based dosing exists for a reason. **Routes:** - **Oral is preferred** if the child can swallow; use liquid formulations for younger children. **Never force a child to take oral medication**; work with the parent and use age-appropriate explanations. - **IV access is more challenging in young children** due to small, mobile veins; use a **22–24 gauge catheter** and consider a **central line** for long-term therapy or vesicant drugs (chemotherapy). - **IM injections are distressing** for children; use when necessary, but prefer SC or IV when available. The **vastus lateralis** (outer thigh) is preferred for infants and young children (< 3 years); **deltoid is small** and appropriate only for very small volumes (≤0.5 mL) in older children. - **Intradermal injections** (allergy tests, TB test) can be given as in adults but require careful site selection and explanation (children may not understand not to scratch). - **Avoid IM/IV in hemophilia** or on anticoagulation without clear indication and physician order. **Medication Preparation and Administration:** - **Never hide medication in food** (except as specifically advised for certain drugs like mixing tablets in applesauce); this violates trust. - **Use syringes for liquid medications**, not household spoons (inaccurate and unsafe). - **Explain in age-appropriate language** (use simple words for toddlers; be honest with older children that "this might sting" for injections). - **Allow parent presence** if possible (provides comfort and helps with compliance). - **Distraction techniques**: counting, breathing exercises, music, or a "comfort object" help children cope with painful procedures. - **Never tell a child a procedure "won't hurt"** if it will; this breaks trust. Say instead, "This might sting for a moment." **Monitoring:** - **Children cannot reliably report side effects or pain**; rely on **parental observation** and your own assessment. Observe for behavior changes (lethargy, irritability), rashes, breathing changes, or unusual cries. - **Measure vital signs** using age-appropriate methods and equipment (smaller cuffs for BP; apical pulse for HR < 12 months). - **Assess hydration** in young children (dry mucous membranes, low urine output, sunken fontanelle [soft spot on infants] are signs of dehydration, important when on diuretics or with fever). - **Monitor for overdose or underdose** carefully; small absolute doses can be easy to miscalculate and have outsized effects in tiny bodies. **Parent/Guardian Education:** - **Teach parents how to give medication** at home (dose measurement, timing, how to give oral medication to a resistant toddler). - **Provide written instructions** in the family's preferred language with clear pictures if available. - **Emphasize the importance of finishing the entire course** of antibiotics, even if the child feels better (critical for preventing resistance). **Geriatric Medication Administration (Age ≥65 Years)** **Age-Related Pharmacokinetic Changes:** Older adults experience **altered drug absorption, distribution, metabolism, and excretion** due to age-related physiologic changes: - **Absorption:** Decreased gastric acidity and slower GI motility may slow oral drug absorption; usually not clinically significant unless absorption is pH-dependent. - **Distribution:** **Decreased total body water** and **increased body fat** mean drugs distribute differently. Fat-soluble drugs (e.g., diazepam) accumulate in fat and have prolonged effects; water-soluble drugs (e.g., digoxin) have smaller volumes of distribution and higher plasma concentrations. - **Metabolism:** **Decreased hepatic function** (reduced blood flow to liver, fewer metabolizing enzymes) slows drug metabolism; drugs accumulate and increase toxicity risk. Examples: warfarin, benzodiazepines, opioids. - **Excretion:** **Decreased renal function** (reduced glomerular filtration rate, reduced tubular secretion) is the most common cause of drug accumulation in older adults. **Estimate the patient's renal function using serum creatinine and calculated creatinine clearance (CrCl)** using the **Cockcroft-Gault equation:** $$\text{CrCl (mL/min)} = \frac{(140 - \text{age}) \times \text{weight (kg)} \times (0.85 \text{ if female})}{72 \times \text{serum creatinine (mg/dL)}}$$ If CrCl < 60 mL/min, the patient has reduced kidney function and may need dose adjustments for renally cleared drugs (many common medications: digoxin, aminoglycosides, NSAIDs, ACE inhibitors). **Always check renal function before administering renally cleared drugs to older adults**. **Dosing Strategy: "Start Low, Go Slow"** - **Use the lowest effective dose** for the shortest duration. - **Increase doses slowly** and titrate based on response; allow time to assess effect before increasing (not "double-dosing" every day). - **Assess for drug accumulation** (signs of toxicity even at standard doses). - **Consider poly pharmacy** (taking multiple drugs simultaneously); the risk of **drug-drug interactions** increases with the number of medications. For example, NSAIDs reduce the effect of ACE inhibitors, and SSRIs plus NSAIDs increase bleeding risk. **High-Risk Medications in Older Adults (Beers Criteria)** The **American Geriatrics Society Beers Criteria** lists medications that are generally **inappropriate for older adults** due to increased risk of adverse effects and minimal benefit. Common examples include: - **Benzodiazepines** (diazepam, lorazepam)—increased fall risk, cognitive impairment, dependency. - **Anticholinergic medications** (diphenhydramine, atropine)—confusion, urinary retention, constipation. - **NSAIDs** (especially long-term)—GI bleeding, renal impairment, hypertension. - **Certain antipsychotics**—increased stroke risk in dementia. - **Long-acting hypoglycemics**—hypoglycemia risk in older adults with limited glycogen reserves. If these drugs are necessary, **use the lowest dose, shortest duration, and monitor closely**. Consider alternatives (e.g., **acetaminophen instead of NSAIDs** for pain; **melatonin or CBT instead of benzodiazepines** for insomnia). **Assessment Before Administration:** - **Verify renal and hepatic function** (check serum creatinine, eGFR, liver enzymes if available). - **Assess for drug interactions** (use a **drug interaction checker** or consult pharmacy). - **Ask about all medications, supplements, and over-the-counter drugs** the patient takes at home (older adults often forget to mention these or see multiple providers without central medication reconciliation). - **Assess fall risk** (if medication is a fall risk—benzodiazepines, antihypertensives, opioids—implement fall precautions). - **Assess cognitive status** (if the patient has dementia, ensure the medication is appropriate and the patient can take it safely; consider supervised administration). - **Monitor for side effects closely**, especially early after starting a new drug. Signs of drug toxicity in older adults can be subtle: **confusion, falls, incontinence, behavioral changes, or apparent worsening of baseline function** may indicate medication toxicity rather than disease progression. **Special Considerations:** - **Large tablets or capsules** are difficult to swallow; ask if the formulation can be changed to liquid or a smaller tablet (but verify it is safe to crush or split; some medications cannot be altered). - **Arthritis or tremors** make self-administration difficult; consider pre-filled syringes for injections or pill organizers for oral medications. **Assess the patient's ability to administer medication** at home; if unable, arrange for a family member, home health nurse, or facility-based supervision. - **Polypharmacy** and cognitive decline increase **medication non-adherence** (patient forgets doses or takes them incorrectly). Use a **pill organizer labeled with days/times** and involve a family member in monitoring. - **Fall risk** from medications is high in older adults (combine antihypertensive + opioid + benzodiazepine = recipe for falls and hip fractures). **Assess fall risk** before and after starting any new medication; implement fall precautions (bed alarm, assist with ambulation, non-slip socks, remove trip hazards). **Medication Administration in Pregnancy and Lactation** **Pregnancy Considerations:** Drugs cross the placenta to varying degrees. The **FDA Pregnancy Categories** (historically A, B, C, D, X; being phased out in favor of **Pregnancy and Lactation Labeling Rule [PLLR]** narrative labeling) guide prescriber decisions: - **Category A (Safest):** No fetal risk demonstrated in controlled studies (rare; examples: prenatal vitamins with folic acid). - **Category B:** Animal studies show no fetal risk, OR animal studies show risk but human studies do not (common; examples: amoxicillin, acetaminophen, most prenatal vitamins). - **Category C:** Animal studies show fetal risk, human data unavailable (use only if benefit outweighs risk; examples: some antiepileptics, ACE inhibitors—latter contraindicated due to teratogenicity). - **Category D:** Evidence of fetal risk, BUT drug may be used in pregnancy if benefit justifies risk (rare in routine care; examples: phenytoin for seizures if no alternatives). - **Category X (Contraindicated):** Proven fetal risk, contraindicated in pregnancy (examples: **ACE inhibitors in 2nd/3rd trimester, warfarin, methotrexate, retinoids, thalidomide, misoprostol, NSAIDs in 3rd trimester, statins, finasteride**). **First trimester** (weeks 1–12) is the period of **organogenesis**; drug exposure carries the highest teratogenicity risk (birth defects). **Second and third trimesters** carry lower teratogenicity risk but higher risk of **fetal toxicity** (growth restriction, premature labor, neonatal effects). **Safe Medications in Pregnancy:** - **Prenatal vitamins** (folic acid to prevent neural tube defects, iron for anemia, calcium). - **Antibiotics:** Penicillins (amoxicillin), cephalosporins, erythromycin (not estolate), azithromycin. - **Analgesics:** Acetaminophen; ibuprofen is acceptable in 1st/2nd trimester (avoid 3rd trimester due to fetal renal effects and premature ductus arteriosus closure). - **Antacids:** Calcium carbonate, magnesium hydroxide; avoid antacids with aluminum or sodium bicarbonate in excess. - **Antihypertensives:** **Methyldopa, labetalol, nifedipine** (safe); avoid ACE inhibitors and ARBs throughout pregnancy. - **Anticonvulsants for seizures:** Some (e.g., lamotrigine, levetiracetam) have lower teratogenicity; phenytoin has known fetal hydantoin syndrome (cleft palate, growth restriction, cardiac defects). **Drugs to Avoid in Pregnancy:** - **ACE inhibitors and ARBs** (especially 2nd/3rd trimester): cause fetal renal failure, oligohydramnios, intrauterine growth restriction, and fetal death. - **NSAIDs** (especially 3rd trimester): close fetal ductus arteriosus, cause renal dysfunction, oligohydramnios, and premature labor. - **Warfarin** (especially 1st trimester): causes fetal warfarin syndrome (bone abnormalities, CNS defects, cardiac defects); use heparin instead (does not cross placenta). - **Methotrexate, retinoids, finasteride, misoprostol, thalidomide:** severe teratogenic effects. - **Statins, ACE inhibitors**: avoid unless critical indication. **Nursing Implications:** - **Always ask if the patient is pregnant or planning pregnancy** before administering any medication. - **Verify the drug is safe in pregnancy** using a pregnancy category resource or consulting pharmacy/OB if uncertain. - **Counsel the patient** about the risk-benefit of continuing/starting medications in pregnancy. - **Monitor for medication effects** during pregnancy (e.g., blood glucose with insulin, BP with antihypertensives, INR with heparin). **Lactation Considerations:** Most medications pass into breast milk to some degree. The **American Academy of Pediatrics (AAP)** and **LactMed database** provide evidence-based information on drug safety during breastfeeding. **Safe Medications During Breastfeeding:** - **Antibiotics:** Penicillins, cephalosporins, macrolides (erythromycin, azithromycin), fluoroquinolones. - **Analgesics:** Acetaminophen, ibuprofen (short-term), morphine (limited transfer). - **Antihypertensives:** Methyldopa, labetalol, nifedipine (minimal infant exposure). - **Prenatal vitamins and minerals.** **Drugs to Avoid or Use With Caution During Breastfeeding:** - **Lithium:** accumulates in milk; may cause infant toxicity (hypothyroidism, cardiac effects); usually contraindicated. - **Warfarin:** safe (minimal milk transfer); heparin preferred. - **Benzodiazepines** (long-term): accumulate in infant; risk of drowsiness, poor feeding. - **Chemotherapy:** contraindicated (toxicity to infant). - **Iodine-containing drugs:** can suppress infant thyroid. - **Tetracyclines:** bind calcium; risk of enamel hypoplasia; avoid until infant teeth erupt. **Timing of Breastfeeding Around Medications:** - If a drug must be taken and has some transfer to milk, **breastfeed before taking the medication** and wait **2–4 hours before the next feeding** (if possible) to allow the drug level in milk to decrease. - For some drugs, waiting is not necessary (low transfer); consult **LactMed**. **Nursing Implications:** - **Ask if the patient is breastfeeding** before administering any medication. - **Verify the drug is safe** in lactation using a resource or consulting pharmacy. - **Counsel the patient** about continuing or stopping breastfeeding if a medication is necessary. - **If the medication is contraindicated**, explore alternatives (e.g., acetaminophen instead of NSAIDs; low-dose warfarin instead of lithium for mood disorder if lithium is the only option—though usually avoided).